{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:44:43Z","timestamp":1761561883413,"version":"build-2065373602"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.cgh.2014.06.022","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:22:43Z","timestamp":1404260563000},"page":"377-385.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B"],"prefix":"10.1016","volume":"13","author":[{"given":"Angeline Oi-Shan","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yock-Young","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cgh.2014.06.022_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1440-1746.2010.06544.x","article-title":"Chronic Hepatitis B in Asia \u2013 new insights from the past decade","volume":"26","author":"Chan","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib2","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1002\/hep.20956","article-title":"Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005","volume":"43","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.06.022_bib4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: 1 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2014.06.022_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an International Workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B","volume":"5","author":"Keefee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2014.06.022_bib9","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A\u00a0randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.20695","article-title":"Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B","volume":"41","author":"Chan","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.cgh.2014.06.022_bib15","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S0168-8278(12)60551-0","article-title":"Improved predictive value for sustained immune control in peginterferon alfa-2a (40KD) (Pegasys)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24","volume":"56","author":"Piratvisuth","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in HBeAg-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib19","unstructured":"Census and Statistics Department. Hong Kong Annual Digest of Statistics 2012. Hong Kong Special Administrative Region, 2012."},{"key":"10.1016\/j.cgh.2014.06.022_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices \u2013 modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2014.06.022_bib21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1524-4733.2009.00605.x","article-title":"The ISPOR good practices for quality improvement of cost-effectiveness research task force report","volume":"12","author":"McGhan","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2014.06.022_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2014.06.022_bib23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleoside\/ nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatits B","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.06.022_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year: in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"year":"2001","series-title":"Report of the Commission on Macroeconomics and Health","author":"Sachs","key":"10.1016\/j.cgh.2014.06.022_bib27"},{"key":"10.1016\/j.cgh.2014.06.022_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0b013e3281108079","article-title":"Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom","volume":"19","author":"Veenstra","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib30","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1440-1746.2006.04539.x","article-title":"Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with HBe-antigen positive chronic hepatitis B in Taiwan","volume":"22","author":"Sullivan","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40273-012-0009-2","article-title":"Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systemic review","volume":"31","author":"Buti","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"Suppl","key":"10.1016\/j.cgh.2014.06.022_bib32","first-page":"409A","article-title":"A\u00a0viral load reduction >3 log at 12 week of entecavir treatment correlated with HBe seroconversion in HBeAg positive patients. Results from a real-life setting study (the ORIENTE study)","volume":"52","author":"Buti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib33","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"Two-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A\u00a0comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chant","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib37","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib40","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib42","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in \u201creal-life\u201d settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2014.06.022_bib43","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1016\/S0168-8278(11)60750-2","article-title":"Outcome of 4-year treatment of entecavir for treatment-na\u00efve chronic hepatitis B","volume":"54","author":"Seto","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2036.2011.04973.x","article-title":"Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"35","author":"Peng","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.06.022_bib45","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hep.22138","article-title":"Health-related quality of life in chronic hepatitis B patients","volume":"47","author":"Ong","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1477-7525-7-52","article-title":"Health-related quality of life of Southern Chinese with chronic hepatitis B infection","volume":"7","author":"Lam","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cgh.2014.06.022_bib48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: 1 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2014.06.022_bib51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in HBeAg-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib52","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cgh.2014.06.022_bib53","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S0168-8278(12)60551-0","article-title":"Improved predictive value for sustained immune control in peginterferon alfa-2a (40KD) (Pegasys)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24","volume":"56","author":"Piratvisuth","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib55","unstructured":"Centre for Health Protection. Department of Health. Surveillance of viral hepatitis in Hong Kong-2012 Update Report. Hong Kong Special Administrative Region, 2013."},{"key":"10.1016\/j.cgh.2014.06.022_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2014.06.022_bib57","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib59","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib60","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.cgh.2014.06.022_bib61","first-page":"409A","article-title":"A\u00a0viral load reduction >3 log at 12 week of entecavir treatment correlated with HBe seroconversion in HBeAg positive patients. Results from a real-life setting study (the ORIENTE study)","volume":"52","author":"Buti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib62","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib63","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2014.06.022_bib65","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib66","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib67","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in \u201creal-life\u201d settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2014.06.022_bib69","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1016\/S0168-8278(11)60750-2","article-title":"Outcome of 4-year treatment of entecavir for treatment-na\u00efve chronic hepatitis B","volume":"54","author":"Seto","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2014.06.022_bib70","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2036.2011.04973.x","article-title":"Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"35","author":"Peng","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.06.022_bib71","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2014.06.022_bib72","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"Two-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.06.022_bib73","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib74","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A\u00a0randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib76","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.20695","article-title":"Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B","volume":"41","author":"Chan","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib77","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A\u00a0comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chant","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.06.022_bib79","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib80","first-page":"1038a","article-title":"Five years of treatment with tenofovir disoproxil (TDF) for chronic hepatitis B infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis","volume":"54","author":"Gane","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficiency of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good\u00a0practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices \u2013 modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2014.06.022_bib83","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1524-4733.2009.00605.x","article-title":"The ISPOR good practices for quality improvement of cost-effectiveness research task force report","volume":"12","author":"McGhan","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2014.06.022_bib84","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cgh.2014.06.022_bib85","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics","volume":"1","author":"Weinstein","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2014.06.022_bib86","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hep.22138","article-title":"Health-related quality of life in chronic hepatitis B patients","volume":"47","author":"Ong","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib87","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1477-7525-7-52","article-title":"Health-related quality of life of Southern Chinese with chronic hepatitis B infection","volume":"7","author":"Lam","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cgh.2014.06.022_bib88","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2014.06.022_bib89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon \u03b1-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B","volume":"56","author":"Bonino","year":"2007","journal-title":"Gut"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651400929X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651400929X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:16:03Z","timestamp":1761542163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235651400929X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S154235651400929X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2014.06.022","relation":{},"ISSN":["1542-3565"],"issn-type":[{"type":"print","value":"1542-3565"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2014.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}